Index finds more pharma companies moving to address access to medicine. Will they now go further?
The 2022 Access to Medicine Index finds more companies widening access in low- and middle-income countries since the pandemic, and asks them to scale it.
Access to Medicine Foundation
1 minute read
The 2022 Access to Medicine Index finds that since the COVID-19 pandemic hit, more pharmaceutical companies have stepped up to make some of their products more widely accessible in low- and middle-income countries (LMICs). If the pandemic is to be a turning point in the fight for equitable access to medicine, companies must now scale their efforts to cover more products in their portfolios, and in a greater number of countries.
Insights
Keep reading
Poor countries desperately need better access to generic medicines
Generic makers showed during the pandemic they can deliver low-cost treatments at scale. The Access to Medicine Foundation asks them to make it the rule.
From Financial Times, republished by the Access to Medicine Foundation
Pooled procurement of drugs in low- and middle-income countries can lower prices and improve access
Evidence from seven countries shows centralised public procurement cuts prices by around 15%, with smaller gains where the supply side is concentrated.
From VoxEU, CEPR
FDA grants accelerated approval for an Alzheimer's disease treatment
The U.S. Food and Drug Administration approves Leqembi (lecanemab) under its accelerated pathway, the second therapy targeting the underlying disease.
From U.S. Food and Drug Administration, via Alzheimers.gov